Side-by-side · Research reference
SurvodutidevsVesugen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED25/54 cited
BAnimal-MechanisticHUMAN-REVIEWED5/43 cited
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
Vesugen
Bioregulatory Tripeptide · Vascular Endothelium
3 AATripeptide
Endothelin-1 ↓Atherosclerotic tissue
Ki-67 ↑Aged endothelium
SQ / IM · Protocol varies
01Mechanism of Action
Parameter
Survodutide
Vesugen
Primary target
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Vascular endothelial cell nucleus — MKI67 gene promoter
Pathway
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑
Downstream effect
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016Khavinson 2014
Feedback intact?
—
Not applicable — does not operate via hormone axis
Origin
—
Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator
Antibody development
—
—
02Dosage Protocols
Parameter
Survodutide
Vesugen
Frequency
Once weekly
Not specified in available literature
Evidence basis
Phase 2 RCT (obesity) · Phase 3 ongoing
Animal models (atherosclerosis, restenosis, aging) · Russian case series
Standard dose (reported)
—
Not standardised — Russian clinical case series
Protocols vary; no FDA-approved regimen.
Duration
—
Case series report treatment courses in elderly arterial insufficiency
Half-life
—
Not reported
Tripeptides typically cleared rapidly.
03Metabolic / Fat Loss Evidence
Parameter
Survodutide
Vesugen
Primary fat target
Total body weight, visceral adipose tissue
—
Weight loss mechanism
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
—
Phase 2 efficacy
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
—
Metabolic markers
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
—
Network meta-analysis
Favorable efficacy profile vs other glucagon receptor agonists
—
Comparative efficacy
Network meta-analysis shows competitive efficacy in GRA class
—
04Side Effects & Safety
Parameter
Survodutide
Vesugen
GI symptoms
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
—
Safety profile
Network meta-analysis: comparable safety to other GRAs
—
Serious adverse events
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
—
Injection site reactions
Expected with subcutaneous administration
—
Glucagon-related effects
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
—
Reported adverse events
—
None documented in available abstracts
Injection site
—
Assumed minimal — typical for small peptides
Long-term safety
—
Unknown — no long-term RCT data
Epigenetic mechanism risk
—
Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised
Absolute Contraindications
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Vesugen
—Relative Contraindications
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
Vesugen
- ·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context
05Administration Protocol
Parameter
Survodutide
Vesugen
1. Reconstitution
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.
3. Timing
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.
4. Storage
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).
5. Needle
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.
—
06Stack Synergy
Survodutide
— no documented stacks
Vesugen
+ Thymalin
Multi-pathwayBoth from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.
- Vesugen
- Per protocol (SQ/IM)
- Thymalin
- Per protocol (SQ/IM)
- Frequency
- Sequential or concurrent per geroprotective protocol
- Primary benefit
- Multi-system age-related decline mitigation (vascular + immune)